Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Case Rep ; 18(1): 250, 2024 May 18.
Article in English | MEDLINE | ID: mdl-38760853

ABSTRACT

INTRODUCTION: Renal cell carcinoma (RCC) is the dominant primary renal malignant neoplasm, encompassing a significant portion of renal tumors. The presence of synchronous yet histologically distinct ipsilateral RCCs, however, is an exceptionally uncommon phenomenon that is rather under-described in the literature regarding etiology, diagnosis, management, and later outcomes during follow-up. CASE PRESENTATION: We aim to present the 9th case of a combination chromophobe RCC (ChRCC) and clear cell RCC (ccRCC) in literature, according to our knowledge, for a 69-year-old North African, Caucasian female patient who, after complaining of loin pain and hematuria, was found to have two right renal masses with preoperative computed tomography (CT) and underwent right radical nephrectomy. Pathological examination later revealed the two renal masses to be of different histologic subtypes. CONCLUSION: The coexistence of dissimilar RCC subtypes can contribute to diverse prognostic implications. Further research should focus on enhancing the complex, yet highly crucial, preoperative detection and pathological examination to differentiate multiple renal lesions. Planning optimal operative techniques (radical or partial nephrectomy), selecting suitable adjuvant regimens, and reporting long-term follow-up outcomes of patients in whom synchronous yet different RCC subtypes were detected are of utmost importance.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , Neoplasms, Multiple Primary , Nephrectomy , Tomography, X-Ray Computed , Humans , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/diagnosis , Female , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/diagnosis , Aged , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/diagnostic imaging
2.
J Histotechnol ; 46(3): 127-138, 2023 09.
Article in English | MEDLINE | ID: mdl-37013797

ABSTRACT

The molecular pathogenesis of osteosarcoma (OS), the most frequent primary malignant bone tumor of all age groups, is still obscure. Since multidrug chemotherapeutic regimens were introduced in the 1970s, survival rates have been stationary. The Wnt-ß-catenin signaling cascade and SOX9 have a significant contribution to skeletal growth, development, and tumorigenesis. In the present work, an attempt was made to examine the role and clinicopathological significance of ß-catenin and SOX9 in 46 cases of pre-neoadjuvant chemotherapy OS tissues compared to 10 cases of non-neoplastic bone. The mRNA levels of both markers were assessed by qRT-PCR, and protein levels of ß-catenin were analyzed by immunohistochemistry. The results were correlated with different clinicopathological parameters. SOX9 mRNA levels were significantly elevated in OS compared to non-neoplastic bone, and higher levels were significantly associated with the occurrence of fluid-fluid levels (indicating blood-containing cystic spaces) and osteolytic radiological pattern. Although ß-catenin mRNA and protein levels were higher in OS compared to non-neoplastic bone, only the protein levels reached statistical significance. Higher ß-catenin mRNA levels were significantly associated with tumor size, while higher protein levels were significantly associated with the histologic subtype, mitotic count, and radiological pattern. No significant association was noted with any of the other evaluated parameters. OS showing higher SOX9 mRNA expression and lower ß-catenin mRNA and protein expression exhibited longer estimated overall survival times approaching statistical significance. To conclude, while high expression of ß-catenin and SOX9 suggests their possible involvement in OS development, their prognostic role may need further research.


Subject(s)
Osteosarcoma , SOX9 Transcription Factor , beta Catenin , Humans , beta Catenin/genetics , beta Catenin/metabolism , beta Catenin/therapeutic use , Cell Line, Tumor , Neoadjuvant Therapy , Osteosarcoma/drug therapy , Osteosarcoma/genetics , Osteosarcoma/metabolism , RNA, Messenger/genetics , SOX9 Transcription Factor/genetics , SOX9 Transcription Factor/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...